Clinical trials
Lung Diseases clinical trials
Below are recruiting lung diseases clinical trials, each written for real people, not researchers. We’re tracking 424 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05391100Recruiting
Screening people with rheumatoid arthritis for lung scarring
This study looks for early lung scarring in people who have rheumatoid arthritis. It may help find a serious lung condition earlier so doctors can watch or treat it sooner.
BudapestAges 40 years+ - NCT06397677Recruiting
Study of Progressive RA Interstitial Lung Disease
This study is looking at people with rheumatoid arthritis (RA) who also have interstitial lung disease (ILD), a condition that causes scarring in the lungs. It aims to understand how the disease changes over time by using imaging and blood tests, without providing any new treatments right now.
San Francisco, CaliforniaAges 18–90 - NCT07613099RecruitingPhase 3
Testing a new PET scan to detect lung and heart scarring
This study tests a new imaging scan (called 18F-FAPI PET/CT) that may help detect scarring in the lungs, heart, or blood vessels. If you have a heart, lung, or blood vessel condition that could cause scarring, this scan might show damage earlier and help doctors plan better treatment.
Bethesda, MarylandAges 18–100 - NCT07561034Recruiting
Home Exercise Program for Pulmonary Hypertension and Lung Disease
This study tests whether daily home exercises can help people with pulmonary hypertension (high blood pressure in the lungs) combined with interstitial lung disease (scarring of lung tissue). Researchers will send you daily messages to support your exercise routine and see if it improves your symptoms and quality of life.
Rochester, New YorkAges 18 years+ - NCT06746077Enrolling by invitation
Lung disease study in children: new ways to understand infections
This study explores how the immune system and lung microbes affect children with lung disease. It uses extra fluid collected during a standard lung exam to look for new treatment targets.
Aarhus NAges birth–17 years - NCT06714123RecruitingPhase 2
Senicapoc for worsening lung scarring
This trial tests if the drug senicapoc can help people whose lung scarring (pulmonary fibrosis) is getting worse despite standard care. It aims to slow down the decline in lung function.
Aarhus NAges 18 years+ - NCT06494033Recruiting
CMV prevention after lung transplant based on immune status
This trial tests whether using a blood test that measures your immune system's ability to fight CMV (a common virus) can guide when to stop anti-CMV drugs after a lung transplant, aiming to prevent the virus from causing disease.
Miami, FloridaAges 18–75 - NCT06297096RecruitingPhase 3
Testing a two-drug combo for lung scarring in scleroderma
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
Warsaw, Masovian VoivodeshipAges 18–74 - NCT03297775Recruiting
Studying rheumatoid arthritis treatment risks for lung scarring
This trial is for people with rheumatoid arthritis (RA) who are at risk for developing interstitial lung disease, which is scarring in the lungs. It aims to better understand why this happens and how to help prevent or manage it.
Aurora, ColoradoAges 45–90 - NCT03683186Enrolling by invitationPhase 3
Long-term study of ralinepag for pulmonary hypertension
This study follows people with pulmonary arterial hypertension (PAH) to see how safe and effective ralinepag is over the long term. It may help your care team understand what to expect from continued treatment and monitoring.
Phoenix, ArizonaAges 18 years+ - NCT05819385Recruiting
Study of lung scarring in immune diseases
This is an observational (non-treatment) study that collects information about how interstitial lung disease (lung scarring) happens in people with certain autoimmune or immune-related conditions. It uses patient interviews or existing medical records to better understand the pattern and causes, which may help future care.
Mexico CityAges 18 years+ - NCT07046234Enrolling by invitation
Lung ultrasound for people with shortness of breath
This trial uses a portable ultrasound at the bedside (called point-of-care lung ultrasound) to quickly examine the lungs of people who are having trouble breathing. The goal is to see how well this test works for finding lung problems in the hospital or clinic.
New Haven, ConnecticutAges 22 years+ - NCT01776398Recruiting
Donating breath, blood, and urine samples for lung research
This study collects airway samples (usually during a bronchoscopy), plus blood and/or urine, to help researchers study lung conditions. It may help advance understanding of lung disease and related biology, but it is not a treatment trial.
New York, New YorkAges 18 years+ - NCT05120934RecruitingPhase 2
Two medicine doses to reduce ILD cough
This Phase 2 study tests whether two different doses of duloxetine and amitriptyline can reduce coughing caused by interstitial lung disease (ILD). If you have had a long-lasting ILD-related cough despite stable ILD treatment, this trial may help find a better way to control your cough.
Rochester, MinnesotaAges 18–75 - NCT07151768Recruiting
Validating a risk score for lung disease patients with pulmonary hypertension
This study is testing whether a new risk score can better predict outcomes for people who have both chronic lung disease and pulmonary hypertension (high blood pressure in the lungs). If you qualify, the researchers will follow your health over time to see how well the score works.
Philadelphia, PennsylvaniaAges 18–99 - NCT07077486RecruitingPhase 4
Testing telitacicept vs cyclophosphamide for lupus lung disease
This trial tests if a new drug called telitacicept works better than a standard lupus medicine (cyclophosphamide) to improve lupus-related lung scarring (interstitial lung disease). It might be an option if your breathing tests are still good enough.
Wuhan, HubeiAges 18–80 - NCT05878717RecruitingPhase 2/Phase 3
Belimumab for adults with scleroderma lung scarring
This Phase 2/3 study tests whether belimumab can improve outcomes and safety in adults with systemic sclerosis (scleroderma) that has caused lung scarring. It may help by reducing active or worsening immune-driven disease in the lungs.
Phoenix, ArizonaAges 18 years+ - NCT05392881Recruiting
Lung disease biobank for adults followed at a university clinic
This study collects and stores samples and health information from adults being followed for interstitial lung disease or certain rare lung conditions. The goal is to help researchers study these diseases over time and improve future care.
Kansas City, KansasAges 18 years+ - NCT04905693Enrolling by invitationPhase 3
Extension inhaled treprostinil study for fibrotic lung disease
This is an add-on (extension) study testing whether continuing inhaled treprostinil can help people with fibrotic lung disease who took part in earlier related studies. It mainly continues treatment and follow-up for eligible participants.
Birmingham, AlabamaAges 40 years+ - NCT04532346RecruitingEarly Phase 1
Hydroxychloroquine for genetic lung disease in children
This early-phase trial studies whether hydroxychloroquine can help children with certain genetic causes of interstitial lung disease (lung scarring/inflammation). It is designed for kids who are currently stable and have not recently taken hydroxychloroquine.
Shanghai, Shanghai MunicipalityAges 1 month–18 years - NCT07673237Recruiting
Remote monitoring for interstitial lung disease
This study tests whether using remote monitoring devices and apps at home can help track your lung health between clinic visits. It may help you stay connected with your care team and catch changes sooner.
San Francisco, CaliforniaAges 18 years+ - NCT06431633RecruitingPhase 3
Sacituzumab and zimberelimab for lung cancer after surgery
This trial tests a combination of two drugs (sacituzumab and zimberelimab) for people with non-small cell lung cancer that was confined to the chest, was surgically removed, but not completely cleared by prior chemotherapy and immunotherapy. The goal is to see if this treatment can help prevent the cancer from coming back.
Alicante, AlicanteAges 18 years+ - NCT07174102Recruiting
Looking at lung scans in rheumatoid arthritis and related diseases
This trial studies lung scans (HRCT) from patients with rheumatoid arthritis, interstitial lung disease, or connective tissue disease to better understand lung involvement. If you have one of these conditions and have had a lung CT, you may be able to help.
PragueAges 18 years+ - NCT06522334Recruiting
Lung disease registry study in Austria
This study collects information from people with interstitial lung disease in Austria to learn more about the condition and how it progresses. It does not involve any experimental treatment.
ViennaAges 18 years+
Hear when a new Lung Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung diseases?
- Yes. Clin2 currently lists 424 recruiting lung diseases studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung diseases trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung diseases trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.